The latest market report published by Acute Market Reports, Inc. “Direct to Consumer Microbiome Analyzing Market By Product (Gut Microbiome Test Kits, Other Microbiome Testing Kits & Health Sample Kits), By Application (Infections, Gut Conditions, Metabolic Disorders, Cardiovascular Disease, Others) – Growth, Future Prospects and Competitive Landscape, 2019 – 2027” the direct to consumer microbiome analyzing market expected to grow at a CAGR of 11.8% during the forecast period from 2019 to 2027.
Browse the full report at “Direct to Consumer Microbiome Analyzing Market”
Market Insights
The global direct to consumer microbiome analyzing market is growing effectively from 2019 to 2027 accredited to the rise in interest for gut microbiome testing kits along with improved technology expansion on a global scale. The microbiome analyzing test kits provide a detailed profile and actionable advice on an individual’s health, nutrition and physical activity. Top companies are differentiating its consumer gut bacteria tests into actionable diagnostics. The personalized health technology companies in the U.S. and U.K are gaining traction in the genomics marketplace, and additionally, they educate their consumers on the big data line to their personal care. Moreover, increasing incidences of genetic disorders along with wide applications of direct to consumer microbiome analyzing in primary detection of oncology, chronic diseases, infections and other genetic disorders will drive the growth of the market during the forecast period.
Top manufacturers are mainly focusing on new product expansion and FDA approval. The increasing number of partnerships with academic research centers and alliance by key laboratories internationally will drive the growth of the market in the near future. For instance, in June 2019, Atlas Biomed Group Limited (personalized health technology company), expanded its offerings for DNA and Microbiome test in Canada, succeeding solid success in the European market. Nevertheless, less awareness related to the pipeline products in the DNA testing industry and less favorable outcomes along with fewer treatment options are few factors restraining the overall growth of the direct to consumer microbiome analyzing market on a global scale. Additionally, the U.S. FDA has now placed regulations for pre-market assessment in case of DNA-based genetic test kits.
Key Market Movements:
- Globally, the direct to consumer microbiome analyzing is growing at a CAGR of 11.8% for the period from 2019 to 2027
- The Europe market will gain traction due to its improved infrastructure, large patient pool and new technology expansion
- Launch of SmartGut and Viome Gut Intelligence™ Test will further spur revenue growth during the forecast period
- Growing number of partnerships, strong pipeline products for direct to consumer microbiome analyzing, and increased personal care expenditure in the developing nations will drive the overall market growth
- Major players in this vertical are uBiome, Inc., Viome, Inc., Atlas Biomed and others
By Product Type (2017–2027; US$ Mn)
- Gut Microbiome Test Kits
- Other Microbiome Testing Kits & Health Sample Kits
By Application Segment (2017–2027; US$ Mn)
- Infections
- Gut Conditions
- Metabolic Disorders
- Cardiovascular Disease
- Others
By Geography Segment (2017-2027; US$ Bn)
- North America
- Europe
- Asia Pacific (APAC)
- Middle East & Africa (MEA)
- Latin America
About Us
Acute Market Reports is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
(US/CANADA) Ph.: +1-855-455-8662
E-mail: sales@acutemarketreports.com